![]() Nuritas has created an AI platform that helps clients discover peptides. ![]() “Our new investors bring a wealth of invaluable expertise, and this latest round will help to build our US headquarters, continue to expand our team, scale our platform to discover more life-changing ingredients and accelerate our route to market,” added Khaldi. ![]() Some of Nuritas’s early backers include Bono and The Edge from U2, Salesforce CEO Marc Benioff and tech entrepreneur Ali Partovi. Existing investors Cultivian Sandbox Ventures and VisVires New Protein also participated. Other investors in the Series B round include Grosvenor’s Wheatsheaf Group, the European Circular Bioeconomy Fund, Singapore-based Vertex Holdings and Nutresa Ventures. “It has been a landmark year, resulting in the expansion of our peptide portfolio, growing the commercial team and developing key global partnerships,” said Dr Nora Khaldi, founder and CEO of Nuritas. A €16m Series A round in 2017 helped the AI and genomics company first take its business global. This brings Nuritas’s total funding to date to $75m and will be used to accelerate the company’s ongoing global expansion, including the establishment of a US headquarters. Nuritas, a global biotech company based in Dublin, has just raised $45m in Series B funding led by Chicago-based VC firm Cleveland Avenue. ![]() Nuritas CEO Dr Nora Khaldi said that the funding will be used to improve its peptide-finding platform and build its new US headquarters. ![]()
0 Comments
Leave a Reply. |